Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 74 PS Ratio is 13.78 as of Jul. 20, 2026, which is 85% below its 10-year median of 89.32. GuruFocus rates ROCO:6733 with a GF Score™ of 74/100 and a GF Value™ of NT$70.49 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 930 Biotechnology companies, BioGend Therapeutics Co ranks worse than 58.6% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioGend Therapeutics Co's share price is NT$24.10.
BioGend Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.75. Hence, BioGend Therapeutics Co's PS Ratio for today is 13.78.
Good Sign:
BioGend Therapeutics Co Ltd stock PS Ratio (=13.38) is close to 10-year low of 13.38.
The historical rank and industry rank for BioGend Therapeutics Co's PS Ratio or its related term are showing as below:
ROCO:6733'
s PS Ratio Range Over the Past 10 Years
Min: 13.55 Med: 89.32 Max: 7428.38
Current: 13.78
During the past 10 years, BioGend Therapeutics Co's highest PS Ratio was 7428.38. The lowest was 13.55. And the median was 89.32.
ROCO:6733's PS Ratio is ranked worse than 58.6% of 930
companies
in the Biotechnology industry
Industry Median: 9.35
vs ROCO:6733: 13.78
During the past 10 years, BioGend Therapeutics Co's highest 3-Year average Revenue per Share Growth Rate was 284.70% per year. The lowest was 80.90% per year. And the median was 151.40% per year.
Back to Basics: PS Ratio
BioGend Therapeutics Co (ROCO:6733) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BioGend Therapeutics Co's Share Price of today is NT$24.10. BioGend Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.75.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BioGend Therapeutics Co (ROCO:6733) has a PS Ratio of 13.78 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioGend Therapeutics Co and its competitors. This is 85% below median its historical median of 89.32. Over the past decade, BioGend Therapeutics Co's PS Ratio has ranged from 13.55 to 7,428.38. According to the industry distribution chart, BioGend Therapeutics Co ranks #545 out of 930 companies in the Biotechnology industry, placing it in the top 58.6%.
Is BioGend Therapeutics Co's PS Ratio too high?
BioGend Therapeutics Co's current PS Ratio of 13.78 is 85% below median its 10-year median of 89.32. Over the past 10 years, this metric has ranged from a low of 13.55 to a high of 7,428.38. The Biotechnology industry median PS Ratio is 9.35. BioGend Therapeutics Co's value of 13.78 is 47.4% above this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #545 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioGend Therapeutics Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #545 out of 930 companies for PS Ratio. This places BioGend Therapeutics Co in the lower half of its industry. The industry median PS Ratio is 9.35. BioGend Therapeutics Co's value of 13.78 is 47.4% above this benchmark. Historically, BioGend Therapeutics Co's own PS Ratio has ranged from 13.55 to 7,428.38 over the past decade. While the company's 10-year median is 89.32 vs. the industry median of 9.35, BioGend Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.35, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current PS Ratio of 13.78 is 47.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current PS Ratio is 13.78, which is 85% below median its own 10-year median of 89.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.49, compared to a current price of NT$24.10 — trading 65.8% below its estimated fair value. The current PS Ratio is 13.78, which is 85% below median its 10-year median of 89.32 and 47.4% above the Biotechnology industry median of 9.35. BioGend Therapeutics Co's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current PS Ratio is 13.78 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$24.10 is trading 65.8% below its estimated GF Value™ of NT$70.49.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
PS Ratio: 13.78 (85% below median its 10-year median of 89.32)
GF Value™: NT$70.49 vs. price of NT$24.10 (65.8% below fair value)
Industry Position: 47.4% above the Biotechnology median (#545 of 930)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
74GF Score
Get the complete analysis for ROCO:6733
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
